Topical clindamycin versus oral tetracycline and placebo in acne vulgaris.
Eighty-seven patients with moderate to severe acne were included in an 8-week randomized double-blind study to compare the efficacies of topically applied clindamycin phosphate 1% b.i.d., oral tetracyclines 500 mg b.i.d. and placebo. Patients were examined every 2 weeks and inflammatory lesions, i.e. papules and pustules were counted in the same area at each examination. Clindamycin phosphate demonstrated a highly significant 72% decrease of inflammatory lesions, as did tetracyclines with a 57% decrease, but not placebo (12%). Clindamycin phosphate was superior to tetracycline. No significant side effects were seen, in particular, no skin side effects.
D000152:Acne Vulgaris / Q000188:drug therapy*; D000284:Administration, Oral; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D002981:Clindamycin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D013752:Tetracycline / Q000008:administration & dosage* / Q000627:therapeutic use
D002981:Clindamycin; C007084:clindamycin phosphate; D013752:Tetracycline